Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (...
Yesterday, the US FDA announced the approval of Seattle Genetics' antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with chemotherapy for patients with previously treated stage III...
New Cleveland Clinic research shows for the first time that FDA-approved ibrutinib (ibrutinib) for lymphoma and leukemia may also help treat the most common and deadly brain tumors, and may one day be...
Bone marrow fibrosis is a rare chronic disease of bone marrow hematopoietic cells. They benefit from JAK2 inhibitor drugs: symptom relief, prolonged survival, and improved quality of life. However, t...
On June 12-13, FDA approved two new indications for K drug, just the day before the K drug was approved for the treatment of cervical cancer. One day later, the US FDA approved pembrolizumab (Keytrud...
In the United States, more than 70,000 people are diagnosed with non-Hodgkin's lymphoma each year, which is caused by excessive proliferation of immune cells in the body's lymph nodes. The most commo...
In recent years, the effect of immune checkpoint inhibitors on the treatment of Hodgkin's lymphoma (HL) is impressive, but the disease still needs to be overcome more thoroughly. Mayo Clinic ’s Lymp...
According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodg...
On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody a...
12 Yue 3 days, a study "The Lancet" published online, for CD30 -positive outer peripheral T -cell lymphoma patients, this rituximab, cyclophosphamide, doxorubicin and prednisone ( A + CHP ) B...